focus
Previous article:
Drug repurposing or repositioning? The language matters
Next article: Lilly's Alzheimer's drug donanemab backed by FDA advisers
Next article: Lilly's Alzheimer's drug donanemab backed by FDA advisers
knowledge
leisure time
-
5 takeaways from STAT's examination of Zynex Medical
2025-10-02 21:12 -
Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable
2025-10-02 20:31 -
STAT Virtual Event: ASCO Recap, Live!
2025-10-02 20:05 -
Stephen Quake on the Chan Zuckerberg quest to conquer disease
2025-10-02 20:01 -
5 takeaways from STAT's examination of Zynex Medical
2025-10-02 19:47 -
How the BIOSECURE Act is already affecting U.S., Chinese life science firms
2025-10-02 19:46